Denali Advisors’s Harvard Bioscience HBIO Stock Holding History

Denali Advisors’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1,820	Closed	-$99.9K	–	501
2023 Q2	$99.9K	Buy	+1,820	New	+$99.9K	0.04%	266

Other funds holding HBIO

272 Capital Dallas, Texas $40M AUM 150.07% 1-Year Est. Return

PAIM

Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Harvey Partners Tarrytown, New York $1.26B AUM 64.44% 1-Year Est. Return

AMH Equity Great Neck, New York $80.3M AUM 78.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Denali Advisors's HBIO Position: Q3 2023 in Review

Denali Advisors sold out of Harvard Bioscience (HBIO) in Q3 2023, closing a stake of 1,820 shares — an estimated $99.9K sold.

Denali Advisors first reported a position in HBIO in Q2 2023 and held it in 1 quarter. The position peaked at $99.9K in Q2 2023. 94 funds tracked by Wall St. Rank hold HBIO as of Q3 2023.

Denali Advisors reported no remaining Harvard Bioscience position as of Q3 2023 after selling out during the quarter.
Denali Advisors sold 1,820 Harvard Bioscience shares in Q3 2023, an estimated $99.9K.
Denali Advisors first reported a position in Harvard Bioscience in Q2 2023 and held it in 1 quarter.
Denali Advisors's Harvard Bioscience position peaked at $99.9K in Q2 2023.
94 funds tracked by Wall St. Rank held Harvard Bioscience as of Q3 2023.

Based on Denali Advisors's 13F filing for Q3 2023, filed 19 Oct 2023.